VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
LFST
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
LFSTLifeStance Health Group, Inc.
$13.77$5.3B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksLFSTCash Flow

LifeStance Health Group, Inc. (LFST) Cash Flow Statement

7Y historyFree accessUpdated daily

Operating cash flow of $37.0M in Q3 2026 ran about 1.65 times net income, though quarterly conversion has been highly volatile, with free cash flow margin swinging from 20.2% in Q2 2026 to 4.9% in Q3 2026 largely due to working capital swings.

Income StatementBalance SheetCash FlowRatios

LFST Cash Flow Statement

Annual statement

LFST Cash Flow Statement

LifeStance Health Group, Inc. (LFST) cash flow statement — 7-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Cash from Operations227.6M146.15M107.26M-16.88M52.79M9.42M-8.53M17.05M
Operating CF Margin %-10.26%8.57%-1.6%6.14%1.41%-2.26%8.02%
Operating CF Growth %1253.97%36.26%735.28%-131.98%460.39%210.39%-150.05%-
Net Income71.91M9.66M-57.44M-186.26M-215.56M-307.2M-38.07M5.67M
Depreciation & Amortization55.94M54.75M70.95M80.44M69.2M54.14M31.05M6.09M
Stock-Based Compensation69.82M74.7M76.17M99.39M187.43M259.44M1.45M54K
Deferred Taxes2.42M2.42M-958K-21.92M-16.73M-26.95M01.76M
Other Non-Cash Items49.3M44.96M45.91M45.2M45.4M27.85M-2.21M478K
Working Capital Changes-21.79M-40.34M-27.37M-33.72M-16.94M2.14M-753K2.99M
Change in Receivables982K36.09M-6.4M-24.18M-21.66M-24.21M-13.3M-5.76M
Change in Inventory00000000
Change in Payables-4.94M-1.56M501K-5.61M7.67M623K829K2.54M
Cash from Investing-57.92M-36.13M-21.57M-60.34M-139.46M-194.08M-861.17M-73.38M
Capital Expenditures-12.2M-36.13M-21.57M-40.52M-79.25M-94.49M-38.07M-14.31M
CapEx % of Revenue0.73%2.54%1.72%3.84%9.22%14.16%10.09%6.74%
Acquisitions-9.59M00-19.82M-60.21M-99.58M-823.1M-59.06M
Investments--------
Other Investing-36.13M0000000
Cash from Financing-154.77M-15.96M-9.95M47.43M47.26M313.86M912.27M48.46M
Debt Issued (Net)-12.69M-7.25M-1.69M55.28M69.56M-223.77M291.41M55.45M
Equity Issued (Net)-122.43M000-904K549.9M20M0
Dividends Paid00000000
Share Repurchases-122.43M000-904K0-1M0
Other Financing-19.65M-8.71M-8.26M-7.86M-21.39M-12.28M600.87M-6.99M
Net Change in Cash14.91M94.07M75.75M-29.8M-39.41M129.2M15.35M-7.86M
Free Cash Flow215.4M110.03M85.69M-57.4M-26.47M-85.07M-46.6M2.73M
FCF Margin %12.85%7.72%6.85%-5.44%-3.08%-12.74%-12.35%1.29%
FCF Growth %80.41%28.39%249.28%-116.9%68.89%-82.56%-1804.43%-
FCF per Share0.550.280.23-0.16-0.07-0.26-0.120.01
FCF Conversion (FCF/Net Income)3.00x15.12x-1.87x0.09x-0.24x-0.03x0.22x3.01x
Interest Paid12.3M17.8M24.99M21.04M14.37M22.41M04.58M
Taxes Paid1.29M1.57M57K80K2.24M1.09M0254K

Key Metrics

Growth RegimeAccelerating
ProfitabilityModerate
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Clinician retention and wage pressure

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Operating Cash Flow Diverges From Net Income

Based on reported quarterly figures, LFST's operating cash flow of $37.0M in Q3 2026 ran about 1.65 times net income of $22.4M, while Q2 2026 OCF reached 4.23 times net income, suggesting cash conversion is highly volatile quarter to quarter.

The gap between net income and operating cash flow is the central signal here, and the ratio swings sharply between quarters rather than converging toward a stable relationship. Much of this variance appears to be driven by working capital movements, which turned from a $47.0M drag in Q1 2025 to a $29.9M contribution in Q2 2026, indicating that reported profits are not translating into cash on a consistent basis. Investors should monitor whether collection timing and payor settlement patterns normalize, as the current pattern warrants further investigation rather than being treated as durable cash generation.

Free Cash Flow Turns Positive but Lumpy

According to the reported figures, LFST's free cash flow margin reached 20.2% in Q2 2026 and 21.7% in Q4 2025, yet fell to 4.9% in Q3 2026, indicating that cash generation has not yet established a steady run rate.

Free cash flow has been positive in most recent quarters, but the 2025 Q1 negative FCF of $10.3M and the sharp swings since then suggest that headline cash generation depends heavily on timing effects rather than purely on the underlying earnings base. Net income remained near breakeven across the period, so the bulk of FCF strength appears to come from working capital and non-cash add-backs, notably stock-based compensation of $18.2M to $19.7M per quarter. This implies that the true cash earnings power is more modest than the peak quarters suggest.

Light Capital Intensity Masks Center Investment

Based on LFST's reported capital expenditures, CapEx ran between 1.6% and 6.6% of revenue across recent quarters, with the Q4 2025 spike to $25.2M appearing to reflect a discrete build-out or lease-related outlay rather than routine maintenance.

Most quarters show capital spending near 2 to 3 percent of revenue, consistent with a low-intensity outpatient model where clinicians rather than equipment drive economics. The Q4 2025 positive CapEx entry is anomalous and may reflect a reclassification or timing item that warrants further investigation. Because D&A has run steadily between $13M and $15M per quarter, maintenance capital needs appear to be roughly covered, though the business does not appear to be generating large growth investment that would explain elevated capital outlays.

Working Capital Drives Quarterly Cash Swings

As reported in financial statements, LFST's working capital changes ranged from a $47.0M outflow in Q1 2025 to a $29.9M inflow in Q2 2026, indicating that receivables and payables timing dominates reported operating cash flow.

The magnitude of working capital swings relative to net income suggests that collections from payors and patients are the primary lever behind quarterly cash results rather than operating margin improvement. Given that management's revenue guidance depends on sustained payor collections, a reversal in working capital could compress cash flow quickly even if earnings hold. Investors should monitor receivable aging and implicit price concession trends to determine whether these inflows are sustainable.

Stock Compensation Flatters Reported Cash Flow

Based on reported figures, LFST's stock-based compensation of $19.7M in Q2 2026 is nearly equal to the period's net income of $23.6M, suggesting a substantial portion of apparent earnings quality rests on non-cash labor costs.

Because SBC is added back in operating cash flow, the cash profile may look stronger than the cash cost of attracting and retaining clinicians and executives would suggest. If equity compensation must be replaced with cash compensation to sustain clinician retention in a competitive wage market, free cash flow could be materially lower than current reported levels. This implies that the headline cash flow conversion may overstate the economic cash earnings available to shareholders.

LFST — Frequently Asked Questions

Quick answers to the most common questions about buying LFST stock.

How much cash does LifeStance Health Group, Inc. (LFST) generate from operations?

LifeStance Health Group, Inc. (LFST) generated $146.2M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is LifeStance Health Group, Inc.'s free cash flow?

LifeStance Health Group, Inc. (LFST) generated $110.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is LifeStance Health Group, Inc.'s capital expenditure (CapEx)?

LifeStance Health Group, Inc. (LFST) spent $36.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.